OSR Health, A Message From the CEO
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares
OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do
CEO Statement to Shareholders
CEO Statement to Shareholders
Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
OSR Holdings, Inc. Granted 180-Day Nasdaq Extension; Reaffirms Strategic Momentum
CEO Statement to Shareholders
OSR Holdings Completes Woori IO Acquisition, Secures Long-Term Shareholder Alignment, and Reviews Strategic Combination of Medical Device Subsidiaries